Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Washington University School of Medicine
University Hospital, Limoges
Eli Lilly and Company
Pfizer
Kelonia Therapeutics, Inc.
Quetzal Therapeutics
Medical College of Wisconsin
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Celgene
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Takeda
Thomas Jefferson University
Medical College of Wisconsin
Cogent Biosciences, Inc.
Eli Lilly and Company
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Kedrion S.p.A.
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Center for International Blood and Marrow Transplant Research
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eli Lilly and Company
Medical College of Wisconsin
University of Michigan Rogel Cancer Center
Nantes University Hospital